ZYBERNO
Stock Report
Updated Sep 1, 2026

CNS Pharmaceuticals, Inc. (CNSP)

Healthcare • NASDAQ

$5.87

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
CNS Pharmaceuticals, Inc. (CNSP) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-204.3%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.21x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-649.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

CNS Pharmaceuticals, Inc. (CNSP) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:5.87
Market Cap:$8.00M

Valuation Multiples (2)

P/B Ratio:0.44x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$8.24M

Price Action & Momentum (3)

Momentum Percentile:8 / 100
% of 52-Week High:55.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-141.9%
Reinvestment Rate:-0.1%
Fundamental Growth Rate (g):0.7%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$641.85
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:95.7%
Latest Earnings Filed:2026-08-12
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:5.86x
Quick Ratio:5.86x
Cash Ratio:5.35x

Leverage Analysis (3)

Debt To Equity Ttm:0.21x
Debt-to-Equity Ratio:0.21x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1,069.48x
Times Interest Earned:-1,069.48

Capital Structure (4)

Working Capital:18,185,000.00
Cash And Cash Equivalents:19,985,000.00
Long Term Debt:$0.00
Net Debt:-$16.25M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$16.91M

Bottom Line Performance (3)

-$16.70M
Income Before Tax:$0.00
Ebitda Ttm:-16,910,033.00

Operating Expenses (5)

Operating Expenses:16,914,719.00
R And D Expense:10,106,713.00
Sga Expense:6,808,006.00
Income Tax Expense:$0.00
Interest Expense:14,948.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$21.94M
Current Assets:$21.92M
Ppe Net:15,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:3,738,000.00
Current Liabilities:3,738,000.00
Long Term Debt:$0.00
Short Term Debt:$3.74M

Equity & Capital (3)

Equity:$18.20M
Retained Earnings:-$107.80M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,738,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$15.22M-$13.83M

Investment Activities (1)

Investing Cash Flow:-$6.18K

Financing Activities (3)

Financing Cash Flow:$404.66K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:500,878.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:4,686.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-35.43
-$35.43
Earnings Per Share Ttm:-$12.25

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$10.13

Book Value & Capital (2)

Book Value Per Share:$13.35
Cash Per Share:14.66

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.1%
Fundamental Growth Rate (g):0.7%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-21.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:CNSP
Company Name:CNS Pharmaceuticals, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:1.36M
Shares Outstanding Basic:6.84M
Shares Outstanding Diluted:6.84M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 17:31:58 UTC
Data Timestamp:2026-08-22T00:24:07.337482
Scroll to Top